NCT05136326View on ClinicalTrials.gov

Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2026

Conditions
Rectal Cancer
Interventions
RADIATION

External-beam radiation

External-beam radiation 50.4 GY (45 Gy in 25 fractions + Boost 5.4 Gy in 3 fractions over 5 weeks)

DRUG

Capecitabine

825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;

DRUG

Temozolomide

75 mg/sqm p.o. 5 days/week for 5 weeks

Trial Locations (1)

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER